334970 — Prestige Biologics Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapSucker Stock

Annual balance sheet for Prestige Biologics, fiscal year end - June 30th, KRW millions except per share, conversion factor applied.

	2022 December 31st	2023 June 30th	2024 June 30th	2025 June 30th	2026 June 30th
Period Length:	12 M	6 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Cash
Cash and Short Term Investments	15,383	45,435	29,507	1,582	6,943
Net Total Accounts Receivable
Net Total Receivables	2,077	2,073	1,654	4,963	6,920
Total Inventory
Prepaid Expenses
Total Other Current Assets
Total Current Assets	29,835	70,242	55,636	40,848	44,901
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	227,107	234,435	233,052	228,406	220,120
Net Intangible Assets
Other Long Term Assets
Total Assets	258,079	305,753	289,414	270,286	266,557
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Current Portion of Long Term Debt / Capital Leases
Total Other Current Liabilities
Total Current Liabilities	32,552	89,098	92,306	102,417	152,498
Long Term Debt
Capital Lease Obligations
Total Long Term Debt
Total Debt
Deferred Income Tax
Total Liabilities	140,468	205,950	217,732	135,083	176,101
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
ESOP Debt Guarantee
Unrealized Gain / Loss
Total Equity	117,611	99,803	71,682	135,203	—
Total Liabilities & Shareholders' Equity	258,079	305,753	289,414	270,286	266,557
Total Common Shares Outstanding